Yicheng Guo

Publications

• Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
• Antibody evasion properties of SARS-CoV-2 Omicron sublineages
• An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses
• Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization
• Meta-Analysis of Parkinson's Disease and Alzheimer's Disease Revealed Commonly Impaired Pathways and Dysregulation of NRF2-Dependent Genes
• Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization
• Prolonged evolution of the memory B cell response induced by a replicating adenovirus-influenza H5 vaccine
• Integrated analysis of ischemic stroke datasets revealed sex and age difference in anti-stroke targets
• In silico identification of anti-cancer compounds and plants from traditional Chinese medicine database
• A new method of identifying glioblastoma subtypes and creation of corresponding animal models
• Comprehensive tissue-specific gene set enrichment analysis and transcription factor analysis of breast cancer by integrating 14 gene expression datasets
• Independent evolution of winner traits without whole genome duplication in Dekkera yeasts
• The identification and molecular mechanism of anti-stroke traditional Chinese medicinal compounds
• Low expression of aging-related NRXN3 is associated with Alzheimer disease: A systematic review and meta-analysis
• De novo variants in congenital diaphragmatic hernia identify MYRF as a new syndrome and reveal genetic overlaps with other developmental disorders
• Identification of metabolism-associated genes and pathways involved in different stages of clear cell renal cell carcinoma
• BRN2 as a key gene drives the early primate telencephalon development
• Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5
• Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir
• SARS-CoV-2 Omicron BA.2.12.1, BA.4, and BA.5 subvariants evolved to extend antibody evasion
• Identification of novel genetic variants in the malaria vaccine candidate PfRh5: structure-guided insights into potential function
• Insights into Body Size Evolution: A Comparative Transcriptome Study on Three Species of Asian Sisoridae Catfish
• cAb-Rep: A Database of Curated Antibody Repertoires for Exploring antibody diversity and Predicting Antibody Prevalence
• Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
• Potent SARS-CoV-2 Neutralizing Antibodies Directed Against Spike N-Terminal Domain Target a Single Supersite
• Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies
• Impaired potency of neutralizing antibodies against cell-cell fusion mediated by SARS-CoV-2
• Impaired potency of neutralizing antibodies against cell–cell fusion mediated by SARS-CoV-2
• Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike
• Vaccine-induced human monoclonal antibodies to PfRH5 show broadly neutralizing activity against P. falciparum clinical isolates
• Resistance of SARS-CoV-2 Omicron Subvariant BA.4.6 to Antibody Neutralization
• Antibody Neutralization of Emerging SARS-CoV-2: EG.5.1 and XBC.1.6
• Antibody Evasion Properties of SARS-CoV-2 Omicron Sublineages
• Recurrent SARS-CoV-2 spike mutations confer growth advantages to select JN.1 sublineages
• XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against emerging SARS-CoV-2 variants
• Recurrent SARS-CoV-2 spike mutations confer growth advantages to select JN.1 sublineages
• Structures of LRP2 reveal a molecular machine for endocytosis
• Antibody neutralisation of emerging SARS-CoV-2 subvariants: EG.5.1 and XBC.1.6
• SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1
• Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants
• Cryo-EM structure of the SARS-CoV-2 Omicron spike
• Activity of Research-Grade Pemivibart against Recent SARS-CoV-2 JN.1 Sublineages
• HIV-1 neutralizing antibodies in SHIV-infected macaques recapitulate structurally divergent modes of human V2 apex recognition with a single D gene
• Potent and broad HIV-1 neutralization in fusion peptide-primed SHIV-infected macaques
• Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking
• Pemivibart is less active against recent SARS-CoV-2 JN.1 sublineages
• Robust SARS-CoV-2 Neutralizing Antibodies Sustained through Three Months Post XBB.1.5 mRNA Vaccine Booster
• Single-Cell Profiling of Bone Marrow B Cells and Early B Cell Developmental Disorders Associated With Systemic Lupus Erythematosus
• Robust SARS-CoV-2-neutralizing antibodies sustained through 6 months post XBB.1.5 mRNA vaccine booster
• SARS-CoV-2 Omicron BA.2.87.1 Exhibits Higher Susceptibility to Serum Neutralization Than EG.5.1 and JN.1
• XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1
• An optimized thermodynamics integration protocol for identifying beneficial mutations in antibody design
• Antibodies that neutralize all current SARS-CoV-2 variants of concern by conformational locking
• Changes in serum-neutralizing antibody potency and breadth post-SARS-CoV-2 mRNA vaccine boost
• Deep immunological imprinting due to the ancestral spike in the current bivalent COVID-19 vaccine
• Deep immunological imprinting due to the ancestral spike in the current bivalent COVID-19 vaccine
• Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2
• Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2
• Influenza C and D Viruses Demonstrated a Differential Respiratory Tissue Tropism in a Comparative Pathogenesis Study in Guinea Pigs
• Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75
• A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses
• Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants
• Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, and BA.5
• Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75
• Changes in Serum Neutralizing Antibody Potency and Breadth Post SARS-CoV-2 mRNA Vaccine Boost
• Development and performance of a point-of-care rapid antigen test for detection of SARS-COV-2 variants
• Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529
• Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation
• Rare variant analysis of 4,241 pulmonary arterial hypertension cases from an international consortium implicate FBLN2, PDGFD and rare de novo variants in PAH
• Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain
• CAb-Rep: A Database of Curated Antibody Repertoires for Exploring antibody diversity and Predicting Antibody Prevalence
• Insights into body size evolution: A comparative transcriptome study on three species of Asian Sisoridae Catfish
• cAb-Rep: A Database of Curated Antibody Repertoires for Exploring Antibody Diversity and Predicting Antibody Prevalence
• VSV-Displayed HIV-1 Envelope Identifies Broadly Neutralizing Antibodies Class-Switched to IgG and IgA
• VRC34-Antibody Lineage Development Reveals How a Required Rare Mutation Shapes the Maturation of a Broad HIV-Neutralizing Lineage
• Tumoral PD-1hiCD8+ T cells are partially exhausted and predict favorable outcome in triple-negative breast cancer
• Rare variant analysis of 4241 pulmonary arterial hypertension cases from an international consortium implicates FBLN2, PDGFD, and rare de novo variants in PAH
• Next-generation sequencing analysis of cellular response to influenza B virus infection
• Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite
• Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite
• Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain
• Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class
• Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class
• Meta-analysis of exhausted CD8+ T cells from Homo sapiens and Mus musculus provides robust targets for immunotherapy
• Isolation and comparative analysis of antibodies that broadly neutralize sarbecoviruses
• Increased resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to antibody neutralization
• Correction to: Rare variant analysis of 4241 pulmonary arterial hypertension cases from an international consortium implicates FBLN2, PDGFD, and rare de novo variants in PAH (Genome Medicine, (2021), 13, 1, (80), 10.1186/s13073-021-00891-1)
• Structural Basis of Antibody Conformation and Stability Modulation by Framework Somatic Hypermutation
• A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses
• Structure-guided insights into potential function of novel genetic variants in the malaria vaccine candidate PfRh5